Annals of Oncology

Papers
(The H4-Index of Annals of Oncology is 88. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
342eP Multiomic characterization of early and metastatic biliary tract cancer (BTC)1494
505eP Real-world efficacy of anlotinib in bevacizumab-treated gastrointestinal cancers1237
501P Bayesian selection of lipidome dynamics features for a K-nearest neighbors (KNN) classifier model of tumor response in patients with advanced gastrointestinal (GI) adenocarcinoma undergoing syste1051
307P AI-driven patient screening for clinical trials in pancreatic cancer: Integrating LLMs with tumor board meetings802
300P Clinical, pathological, and genomic biomarkers associated with early recurrence in resected localized pancreatic ductal adenocarcinoma (L-PDAC)720
327P Real world evidence of outcomes and treatment patterns for advanced biliary tract cancer in Saudi Arabia630
16P Early ctDNA decrease predicts survival in MSI metastatic colorectal cancer treated with immunotherapy597
139eP Real-world practice of MSI/MMR testing and treatment patterns in colorectal cancer: A nationwide survey in China (SUMMER study)577
251P Clinical outcomes of rectal squamous cell carcinoma in British Columbia, Canada562
92P Real-world evidence of a tissue-free ctDNA-based minimal residual disease (MRD) testing in colorectal cancer (CRC): Insights from an Indian cohort519
195P Risk factors in patients with hepatocellular carcinoma: A German claims data analysis483
285P Gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer: A multicenter, single-arm, phase I/II trial423
77P Chronologic improvement in survival of first-line oxaliplatin based chemotherapy + targeted therapy for metastatic colorectal cancer (mCRC): Analysis of the ARCAD database402
178P Efficacy and safety of laparoscopic liver resection versus radiofrequency ablation in patients with early and small hepatocellular carcinoma: An updated meta-analysis and meta-regression of obser401
476P How to predict microsatellite instability (MSI) status in locally advanced gastric cancer? A preoperative CT-based proposal370
19P Adjuvant chemotherapy in colon cancer: 6 months better than 3?365
215P Peptide receptor radionuclide therapy versus capecitabine/temozolomide for the treatment of metastatic pancreatic neuroendocrine tumors356
225P Nuclear exporter protein exportin 1 (XPO1) as a novel therapeutic target in pancreatic neuroendocrine tumors329
468P Association of prior and concurrent malignancies with overall survival in a large European single-center gastroesophageal cancer cohort309
459P Layer analysis based on RNA-seq data of TCGA reveals gastric cancer's molecular complexity288
133P The role of determining the diagnostic value of circulating tumor DNA (ctDNA) and natural blood killers (NK) in the diagnosis of precancerous diseases of the colon and colorectal cancer (CRC)287
45P Neoadjuvant immunotherapy with prolgolimab in locally advanced MSI/dMMR colorectal cancer: Safety and efficacy analysis287
Identifying genetic loci associated with an increased risk for early-onset colorectal cancer285
13P Genomic signatures of recurrence after resection of node-negative colorectal cancer272
Table of Contents251
386P Exploratory biomarker analysis based on the PREDICT trial (AIO-PAK-0216) for response prediction to second-line nal-IRI/5-FU/FA chemotherapy (CTX) in metastatic PDAC patients (mPDAC Pts)233
546P An artificial intelligence system integrating deep learning-proteomics, pathomics and clinicopathological features to determine risk of T1 colorectal cancer metastasis to lymph node229
CN100 Scalp cooling in breast cancer: What are women's experiences? A description and qualitative study225
28P Targeting YAP1 as a biomarker of resistance and therapeutic strategy in melanoma immunotherapy199
1906P ESMO-ESTRO consensus recommendations regarding the safety of combining radiotherapy with targeted agents or immunotherapy197
897P Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma189
1739P Linnovate: A phase I/II study of safety/efficacy using lurbinectedin combined with ipilimumab and nivolumab for advanced soft tissue sarcoma (NCT05876715) - Interim analysis of phase I part184
1069TiP A phase I/IIa dose escalation and expansion study of 23ME-01473, an anti-ULBP6/2/5 antibody, for patients with advanced solid malignancies181
1768P Desmoid tumors: Experience of a Spanish reference center180
1339P Impact of KRAS, STK11, and KEAP1 co-mutations on survival outcome and response to chemoimmunotherapy in patients with metastatic NSCLC178
1270P Lazertinib for patients with NSCLC harboring uncommon EGFR mutations: A single-arm, phase II multi-center trial175
2007P Similar genetic profile in early and late-stage urothelial tract cancer suggests that early genomic testing bears the potential of timely personalized treatment in clinical trials175
420P An exosome-based ESR1 monitoring RT-qPCR kit that rapidly and accurately detects acquired resistance variants at ≤ 0.1% frequency in liquid biopsy samples170
87P Application of tissue and liquid-based next generation sequencing (NGS) for comprehensive genomic profiling: Evaluating the clinical value of ctDNA technology in treatment decision making169
199P Association of homologous recombination deficiency status with outcomes for ovarian cancer patients treated with olaparib, and exploration of other biomarkers of relapse and survival169
913P Characterisation of genomic biomarkers of response to cetuximab versus cisplatin in concomitance with radiotherapy in locally advanced squamous head and neck cancer166
CN107 The effect of Orem-based oral self-care protocol on high-dose chemotherapy-related oral mucositis and self-care agency in patients for hematologic malignancies: A randomized controlled study165
653P A phase I dose escalation study of EBC-129, a first-in class, anti N-glycosylated CEACAM5 & CEACAM6 antibody-drug conjugate (ADC) in patients with solid tumors165
1915P Phase I trial of adjuvant pembrolizumab after radiation therapy for lung-intact malignant pleural mesothelioma165
1990P MRG002-HER2 ADC combined with pucotenlimab (a PD-1 inhibitor), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase I/II study152
568P Risk factors for recurrence after surgery for rectal cancer in a modern, nationwide population-based cohort152
1163P Prognostic value of systemic inflammatory index (SII) in neuroendocrine tumors (NETs) treated with peptide receptor radionuclide therapy (PRRT)147
1203P Analytical evaluation of whole genome sequencing for acute myeloid leukemia141
473P A novel machine learning (ML) model integrating clinical and molecular data to predict response to second-line treatment in recurrent IDHwt-glioblastoma (rGBM)141
1493P The Italian version of the FAMCARE-P13 questionnaire: A validation study137
1992P Real-world (RW) characteristics and outcomes in patients (pts) with muscle-invasive urothelial carcinoma (MIUC) treated with adjuvant nivolumab (NIVO) with or without neoadjuvant chemotherapy (N136
2009P PUNCH02: Primary results from a phase II study of tislelizumab combined with disitamab vedotin as a bladder preservation therapy for urine tumor DNA (utDNA)-defined clinical complete response (c134
1385P Uncovering resistance mechanisms and vulnerabilities of KEAP1 mutated lung adenocarcinoma133
CN11 The challenges of the multidisciplinary work of nurses in the international department at Gustave Roussy Cancer Campus130
Imatinib’s last lessons? A roadmap to cure129
495TiP CLARITY-Gastric 01: A randomised phase III study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junct128
344P Treatment intensification patterns in Asian patients with metastatic hormone sensitive prostate cancer (mHSPC)127
193P DCLK1’s kinase activity drives its pro-stemness effect in esophageal squamous cell carcinoma121
415P Preliminary safety and efficacy results from phase II study pulsed radiotherapy with tislelizumab in patients with recurrent head & neck cancer119
503P Retrospective evaluation of real-world experience and usefulness of implementing next-generation sequencing in clinical oncology: Insights from a developing Asian country118
643P Resistance mechanisms and efficacy of first-line (1L) alectinib in patients (pts) with ALK-rearranged non-small cell lung cancer (ALK+ NSCLC): Second interim analysis of ALCURE116
387P COL4A6 promotes tumor progression and chemoresistance in ovarian cancer by activation DDR1 pathway114
565P Prevalence of multi-drug resistant bacteria among neutropenic cancer patients and its association with 30-day mortality: A single centre study from a regional cancer centre113
1829P Exposure-safety analyses of talazoparib in combination of enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in TALAPRO-2 trial111
501P Comparison between tissue and ctDNA for detecting tumor mutation burden (TMB) across solid tumors: A single centre study from India111
259P Irinotecan liposome-based regimen in Chinese patients with advanced pancreatic cancer: A prospective, multi-center, observational real-world study111
217P The efficacy and safety of tislelizumab as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after radical reaction110
349P Predictive gene signature in primary prostate cancer associated with regional lymph-node metastasis using both mRNA and miRNA profiling110
475P Impact of palliative care on the quality of life in advanced non-small cell lung cancer patients: A longitudinal study109
339P Comparison of stereotactic body radiation therapy(SBRT) and radical prostatectomy (RP) in high-risk/very high-risk prostate cancer: A large multi-center comparative analysis using propensity scor108
596P Innovative multimodal deep-learning model for real-time prediction of recurrence in early-stage NSCLC107
546P Multifaceted challenges in patient-centered oral cavity cancer care: An Asia-Pacific cross-sectional study with patients, caregivers, and healthcare professionals103
699P Osimertinib combined with chemotherapy as first-line treatment in EGFR-mutant advanced NSCLC patients: The first real-world analysis in China102
581P Informal caregiver mental health and time cost for stomach and pancreatic cancer care101
231P CT image-based artificial intelligence quantification of intratumoral heterogeneity for predicting treatment response to immunotherapy combined with anti-angiogenic drugs in hepatocellular carcin101
709P The impact of antibiotic use on ICI plus chemotherapy versus chemotherapy in NSCLC patients with PD-L1 expression of 1% to 49%100
237P Radiotherapy with or without Immune checkpoint inhibitors and tyrosine kinase inhibitors in hepatocellular carcinoma with severe macrovascular invasion: A retrospective cohort study98
589P Patient centricity in cancer: Overview past and current applications of patient reported outcomes96
131MO Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Patient reported 95
178P KEYNOTE-859 update: Pembrolizumab + chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer94
483MO RNA-based multiplex polymerase chain reaction and sequencing to detect fusion genes in melanoma94
482MO Clinical usefulness of next-generation sequencing for metastatic or unresectable gastric cancer in molecular profiling-guided therapy era93
517P Circulating tumor DNA dynamics to predict response to tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer: An interim report92
781P Prognostic role of targeted amino acids as oncometabolites in acute lymphoblastic leukemia91
162P Efficacy of perioperative FLOT in gastric carcinoma and gastroesophageal junction carcinoma in achieving PCR: Retrospective analysis in a single institution experience90
554P Clinical outcomes of treating patients in prone compared to supine position for breast radiotherapy: A systematic review and meta-analysis90
666P Final results of phase I/II study of NUC-7738 as monotherapy and in combination with pembrolizumab: Anti-tumor immune response in PD-1 inhibitor-resistant patients89
285O Prevalence of homologous recombination deficiency in ovarian, primary peritoneal, and/or fallopian tube cancer: Results from the international HALO study89
0.2135488986969